One-Year Outcomes and Satisfaction Following Non-Linear Aspheric Micro-Monovision LASIK (PRESBYOND) for Myopic and Hyperopic Presbyopia Authors: Zofia Pniakowska, Barbara Czarnota-Nowakowska, Nabila Jones, Joanna Wierzbowska Published: 2026 ABSTRACT PurposeTo investigate clinical outcomes and satisfaction following non-linear aspheric micro-monovision LASIK for presbyopia.Patients and MethodsRetrospective single-center study of myopic and hyperopic presbyopic patients treated with LASIK-induced micro-monovision combined with non-linear aspheric ablation profiles (PRESBYOND® Laser Blended Vision, Carl Zeiss Meditec AG) at Optegra Eye Clinic, Poland, between January 2019 and December 2023. Dominant eyes were targeted for plano; non-dominant eyes were targeted for −0.40 to −2.00 diopters (D). Visual acuity (VA) was assessed at 1, 3, and 12 months. Patients completed a purpose-made (non-validated) questionnaire assessing subjective experience and satisfaction at 3–6 months and 12 months postoperatively.ResultsThe study included 638 eyes of 319 patients (442 myopic eyes and 196 hyperopic eyes). At 12 months, binocular uncorrected distance VA was 20/20 or better in 98% of myopic patients and 93% of hyperopic patients. Binocular uncorrected near VA was N6 or better in 99% of myopic patients and 96% of hyperopic patients. All eyes were within ±1.00 D of intended spherical equivalent in both groups. No eyes in the myopia group and one eye in the hyperopia group lost two or more lines of corrected distance VA. Seventy out of 100 respondents at the 12-month visit (70%) experienced an improvement in vision within hours to a few days. Vision quality was rated satisfactory to excellent by 92% of patients and 89% were happy with the procedure.ConclusionThe findings of this retrospective study suggest that non-linear aspheric micro-monovision LASIK can achieve safe and effective correction of myopic and hyperopic presbyopia with high patient satisfaction up to one year postoperatively. Prospective studies using validated questionnaires are required to further characterize patient-reported outcomes with this procedure. Introduction Presbyopia is the age-related loss of accommodation. Uncorrected presbyopia is the most prevalent cause of vision impairment globally, affecting approximately 826 million people worldwide.1 The gradual weakening and eventual loss of accommodation manifests as difficulty performing near and intermediate vision tasks like reading fine print or using electronic devices, which can lead to reductions in quality of life (QOL) and overall productivity.2,3 Although presbyopia is commonly and effectively treated with glasses, the inconvenience and psychosocial issues related to spectacle usage may also negatively impact QOL.4 Modern refractive surgery offers several treatment options for spectacle independence, of which the most widely used methods act by achieving monovision, multifocality, and increased depth of focus through corneal ablation or intraocular lens implantation.5–8 One corneal-based surgical approach is presbyopia LASIK (laser in situ keratomileusis) using micro-monovision combined with non-linear aspheric ablation profiles (PRESBYOND® Laser Blended Vision, Carl Zeiss Meditec AG, Jena, Germany). This procedure increases the depth of focus through controlled induction of spherical aberrations (SA), creating a blend zone between both eyes for a continuous range of vision.9 The combination of induced SA and micro-monovision can achieve spectacle independence at distance, intermediate, and near ranges, while preserving visual quality, contrast sensitivity, and stereoacuity,10–14 setting it apart from traditional monovision that can be associated with reduced contrast sensitivity and stereopsis.15,16 While there is ample evidence to support safety and efficacy, patient-reported outcomes (PROs) with this treatment remain less defined. PROs assess patients’ self-reported experiences of a condition or procedure, enabling estimation of patients’ satisfaction, QOL, and functionality,17 which cannot be captured adequately using clinician-reported measurements. Studies documenting PROs with non-linear aspheric micro-monovision LASIK mostly report overall satisfaction scores,12,14,18–21 with some reporting visual function-related data,10–13,20,21 ocular symptoms,12 and visual complaints.11–13,21 To the authors’ knowledge, no studies have reported preoperative patient expectations or patient experiences during the procedure, which are necessary to determine the treatment’s effectiveness in meeting patients’ needs. As several studies had short-term follow-ups, results may not accurately reflect PROs after neuroadaptation to monovision LASIK, which can take up to 12 months.16,22 Additionally, satisfaction after monovision LASIK may vary between myopes and hyperopes;7 since micro-monovision LASIK induces positive SA in myopic eyes and negative SA in hyperopic eyes, studies including both populations are required to establish any influence of refractive error and SA sign on PROs. The current study aims to strengthen the evidence base by reporting real-world effectiveness and safety along with patient expectations, experience, and satisfaction up to 12 months following non-linear aspheric micro-monovision LASIK in presbyopic patients with myopia and hyperopia. Patients and Methods Study Design and Subjects This was a retrospective, longitudinal study of patients undergoing treatment for myopic or hyperopic presbyopia. The study complied with the standards of the Declaration of Helsinki, and received ethical approval with exemption as a non-experimental study from the Bioethics Committee of the Medical University of Łódź, Poland (exemption number RNN/35/25/KE/KE, 14 January 2025). Informed consent for the procedure was obtained from all patients. The study included patients treated with PRESBYOND between January 2019 and December 2023 at the Optegra Eye Clinic in Poznań, Poland. Inclusion criteria were presbyopic patients suitable for LASIK, myopia up to −8.50 diopters (D), hyperopia up to +4.75 D, astigmatism up to 3.25 D, preoperative corrected distance visual acuity of 20/25 or better, and minimum 12-month postoperative follow-up. The population was categorized based on preoperative refractive error using negative cylinder notation. Refractive groups were defined according to the manifest spherical component: eyes with a sphere value ≥ 0.00 D were classified as hyperopic, and eyes with a sphere value < 0.00 D were classified as myopic. Eyes with mixed astigmatism (ie, one hyperopic and one myopic principal meridian) were included in the hyperopic group if the manifest spherical component was ≥ 0.00 D, according to the predefined classification, which was selected to maintain consistency with the treatment planning approach used clinically in our practice and in the literature.11 Exclusion criteria were ocular comorbidities affecting vision, such as cataract, glaucoma, amblyopia, retinal and corneal pathology, strabismus or compromised binocular vision; history of refractive or other ocular surgery; and acute or chronic systemic illnesses. Patients who did not complete 12 months follow-up or who skipped any follow-up visit were also excluded. Preoperative Evaluation A comprehensive ophthalmological examination was performed preoperatively, including manifest and cycloplegic refraction; monocular and binocular uncorrected and corrected distance visual acuity (UDVA and CDVA) with Snellen charts at a standard distance of 6 meters; uncorrected near visual acuity (UNVA) with Snellen charts at 40 cm; slit-lamp microscopy of the anterior and posterior segments; intraocular pressure measurement corrected for central corneal thickness (NT-530 P, NIDEK Co., Ltd, Tokyo, Japan); and corneal and anterior segment tomography including keratometry (Pentacam, Oculus Optikgeräte GmbH, Wetzlar, Germany; Zeiss Cirrus 500/5000, Carl Zeiss Meditec, Inc.), aberrometry, and pupillometry (Osiris Aberrometer, Costruzioni Strumenti Oftalmici, Florence, Italy; Zeiss Atlas 500, Carl Zeiss Meditec, Inc.). Ocular Dominance Testing The dominant eye was determined using three sensory tests (hole, pointing, and shooting) and one motor test (fogging). Dominance was verified if the result was the same for all four tests. If at least one test was inconsistent and affected the results of micro-anisometropia testing (described in the following paragraph), a contact lens test lasting 2–5 days was performed, with a plano target on one eye and a myopic target on the other in two options on each eye to determine the option providing the best visual comfort. Micro-Anisometropia Testing Tolerance to micro-anisometropia was tested with the dominant eye corrected to plano and the non-dominant eye correction ranging from −0.40 D to −2.00 D as described in previous studies.23,24 The intended micro-anisometropia was strictly determined by the option that produced minimal to no cross-blur (ie, maximal interocular blur suppression). In cases of reverse monovision tolerance (myopic target on the dominant eye) or inconsistent eye dominance tests, a contact lens test was performed, as previously described, to verify the most natural visual option for the patient. Surgical Procedure All surgical procedures were performed by an experienced refractive surgeon (BCN). Non-linear aspheric ablation profiles were designed using the Custom Refractive Software (CRS) Master system (Carl Zeiss Meditec AG, Jena, Germany) based on preoperative aberrometry data. Flaps were created using the VisuMax femtosecond laser (Carl Zeiss Meditec AG). Flap thickness ranged from 100 μm to 115 μm, while flap diameter ranged from 8.2 mm to 8.8 mm in the myopia group, and from 8.9 mm to 9.0 mm in the hyperopia group. The MEL 90 excimer laser (Carl Zeiss Meditec AG) was used to perform corneal ablation in an optical zone from 6.0 mm to 6.5 mm in myopic eyes, and from 6.5 mm to 7.0 mm in hyperopic eyes. Postoperative Evaluation Postoperatively, dexamethasone, tobramycin and moxifloxacin eye drops were applied four times daily for one week. Patients were examined at postoperative day 1 and at 1, 3, and 12 months after treatment. Assessments included slit lamp examination of anterior and posterior segments, refraction, monocular and binocular UDVA, CDVA, and UNVA, intraocular pressure, corneal topography, anterior segment optical coherence tomography and aberrometry assessment. PROs, including operative and postoperative experience, quality of vision, and satisfaction were collected using a purpose-made questionnaire with closed-ended questions at two timepoints: (i) Between the 3- and 6-month visits, and (ii) 12 months after surgery. Statistical Analysis Data entry and descriptive statistical analyses were performed with Microsoft Excel 2010 (Microsoft Corporation). Continuous variables are expressed as mean ± standard deviation (SD), while categorical variables are reported as percentages. Sample size and statistical power were not estimated a priori and analyses did not consider inter-eye correlation, as the study aimed to describe real-world outcomes in all eligible patients rather than to test a statistical hypothesis. Data from dominant and non-dominant eyes were analyzed separately. Visual acuity measurements were converted to logarithm of the minimum angle of resolution (logMAR) values for analysis. Refractive surgery outcomes were evaluated according to the Standard Graphs for Reporting Refractive Surgery defined by Waring.25 Results The original study population comprised 340 patients (680 eyes), including 234 patients (468 eyes) with myopia and 106 patients (212 eyes) with hyperopia. Of these, 319 patients (638 eyes) with a mean age of 47.0±5.0 years (range: 36–65 years) completed the 12-month follow-up and comprised the final study cohort (Figure 1). The rate of patients lost to follow-up was 6.2%. The myopia group comprised 221 patients (442 eyes; mean age: 45.0±4.0 years), while the hyperopia group comprised 98 patients (196 eyes; mean age: 52.0±4.0 years). Among the 196 eyes included in the hyperopia group, 9 eyes (4.6%) had mixed astigmatism preoperatively. Eyes with a manifest spherical component of ≥0.00 D were assigned to the hyperopia group in accordance with the predefined classification criteria; therefore, all eyes with mixed astigmatism were included in the hyperopic cohort. The preoperative characteristics of both groups are presented in Table 1. Mean preoperative spherical equivalent (SEQ) was −4.20±1.94 D in myopic eyes and +1.59±0.94 D in hyperopic eyes. Figure 1Flowchart illustrating patient selection and respondents to patient-reported outcome (PRO) questionnaire at each timepoint.Flowchart of patient selection and PRO questionnaire respondents over time.Table 1Population DemographicsCategoryMyopia GroupHyperopia GroupEyes (patients)442 (221)196 (98)Sex: male (%)/female (%)62 (28)/159 (72)49 (50)/49 (50)Age (y), mean±SD (range)45.0 ± 4.0 (36 to 59)52.0±4.0 (40 to 65)Sphere (D), mean±SD (range)−3.81 ± 1.98 (−0.25 to −8.50)+1.82 ± 0.92 (0.00 to +4.75)Cylinder (D), mean±SD (range)−0.78 ± 0.61 (0.00 to −3.00)−0.46 ± 0.45 (0.00 to −3.25)SEQ (D), mean±SD (range)−4.20 ± 1.94 (−0.62 to −9.00)+1.59 ± 0.94 (−0.75 to +4.25)Mean K (D), mean±SD (range)43.77 ± 1.31 (40.75 to 48.25)43.08 ± 1.36 (39.50 to 46.50)Scotopic pupil diameter (mm), mean±SD (range)5.74 ± 0.95 (2.74 to 7.97)5.22 ± 0.92 (2.78 to 7.39)Optical zone (mm), mean±SD (range)6.21 ± 0.25 (6.00 to 6.50)6.80 ± 0.21 (6.50 to 7.00)Pachymetry (μm), mean±SD (range)544.00 ± 30.29 (464 to 619)549.00 ± 30.00 (478 to 635)WTW (mm), mean±SD (range)12.15 ± 0.36 (11.2 to 13.4)12.09 ± 0.36 (11.3 to 12.9)Abbreviations: D, Diopter; SD, Standard deviation; SEQ, Spherical equivalent; K, Keratometry; WTW, White-to-white. Flowchart illustrating patient selection and respondents to patient-reported outcome (PRO) questionnaire at each timepoint. Table 1Population DemographicsCategoryMyopia GroupHyperopia GroupEyes (patients)442 (221)196 (98)Sex: male (%)/female (%)62 (28)/159 (72)49 (50)/49 (50)Age (y), mean±SD (range)45.0 ± 4.0 (36 to 59)52.0±4.0 (40 to 65)Sphere (D), mean±SD (range)−3.81 ± 1.98 (−0.25 to −8.50)+1.82 ± 0.92 (0.00 to +4.75)Cylinder (D), mean±SD (range)−0.78 ± 0.61 (0.00 to −3.00)−0.46 ± 0.45 (0.00 to −3.25)SEQ (D), mean±SD (range)−4.20 ± 1.94 (−0.62 to −9.00)+1.59 ± 0.94 (−0.75 to +4.25)Mean K (D), mean±SD (range)43.77 ± 1.31 (40.75 to 48.25)43.08 ± 1.36 (39.50 to 46.50)Scotopic pupil diameter (mm), mean±SD (range)5.74 ± 0.95 (2.74 to 7.97)5.22 ± 0.92 (2.78 to 7.39)Optical zone (mm), mean±SD (range)6.21 ± 0.25 (6.00 to 6.50)6.80 ± 0.21 (6.50 to 7.00)Pachymetry (μm), mean±SD (range)544.00 ± 30.29 (464 to 619)549.00 ± 30.00 (478 to 635)WTW (mm), mean±SD (range)12.15 ± 0.36 (11.2 to 13.4)12.09 ± 0.36 (11.3 to 12.9)Abbreviations: D, Diopter; SD, Standard deviation; SEQ, Spherical equivalent; K, Keratometry; WTW, White-to-white. Population Demographics Abbreviations: D, Diopter; SD, Standard deviation; SEQ, Spherical equivalent; K, Keratometry; WTW, White-to-white. Visual Outcomes Table 2 shows visual outcomes in distance eyes (dominant), near eyes (non-dominant), and binocularly in both groups. Figures 2 and 3 show the Standard Graphs for Reporting Refractive Surgery Outcomes for the myopia and hyperopia groups, respectively. Figure 2Standard graphs reporting refractive outcomes in myopia group at 12 Months. (A) Cumulative histogram of postoperative uncorrected distance visual acuity (UDVA) and preoperative corrected distance visual acuity (CDVA) in distance eyes. (B) Comparison of postoperative UDVA and preoperative CDVA in distance eyes. (C) Histogram showing change in CDVA for all myopia eyes. (D) Scatter plot showing attempted vs achieved spherical equivalent (SEQ) for all myopia eyes. (The blue line indicates attempted SEQ= achieved SEQ, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line.) (E) Histogram showing accuracy to intended SEQ for all myopia eyes. (F) Stability of SEQ in all myopia eyes. The line plot (red line) shows the trend of mean SEQ over time. (G) Histogram showing preoperative and postoperative refractive astigmatism in all myopia eyes. (H) Scatter plot showing target induced astigmatism (TIA) vs surgically induced astigmatism (SIA) for the myopic astigmatic eyes. (The blue line indicates TIA = SIA, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line). (I) Histogram showing angle of error of refractive astigmatism for the myopic astigmatic eyes.The image A showing a grouped bar chart of cumulative percent of eyes versus cumulative Snellen visual acuity 20 over x or better. Horizontal axis label, Cumulative Snellen VA 20 over x or better, with categories 20 over 12.5, 20 over 16, 20 over 20, 20 over 25, 20 over 32, 20 over 40. Vertical axis label, Cumulative percent of Eyes, percent, from 0 percent to 100 percent. Bars labeled Postop UDVA and Preop CDVA. Values at 20 over 12.5: Postop UDVA 4 percent, Preop CDVA 0 percent. 20 over 16: Postop UDVA 43 percent, Preop CDVA 0 percent. 20 over 20: Postop UDVA 90 percent, Preop CDVA 100 percent. 20 over 25: Postop UDVA 93 percent, Preop CDVA 100 percent. 20 over 32: Postop UDVA 95 percent, Preop CDVA 100 percent. 20 over 40: Postop UDVA 96 percent, Preop CDVA 100 percent. The image B showing a bar chart of percent of eyes versus difference between UDVA and CDVA in Snellen lines. Horizontal axis label, Difference between UDVA and CDVA Snellen Lines, categories 3 or More Worse, 2 Worse, 1 Worse, Same, 1 or More Better. Vertical axis label, percent of Eyes, percent, from 0 percent to 60 percent. Bar values: 3 or More Worse 2 percent, 2 Worse 2 percent, 1 Worse 3 percent, Same 42 percent, 1 or More Better 51 percent. The image C showing a bar chart of percent of eyes versus change in Snellen lines of CDVA. Horizontal axis label, Change in Snellen Lines of CDVA, categories Loss 3 or More, Loss 2 or More, Loss 1, No Change, Gain 1, Gain 2 or More, Gain 3 or More. Vertical axis label, percent of Eyes, percent, from 0 percent to 100 percent. Bar values: Loss 3 or More 0.0 percent, Loss 2 or More 0.0 percent, Loss 1 1 percent, No Change 87 percent, Gain 1 11 percent, Gain 2 or More 0 percent, Gain 3 or More 1 percent. The image D showing a scatter plot of achieved spherical equivalent versus attempted spherical equivalent. Horizontal axis label, Attempted SEQ Diopters, from positive 1 to negative 9. Vertical axis label, Achieved SEQ Diopters, from positive 1 to negative 9. Diagonal reference lines and a regression line are shown with text, y equals 0.9896x plus 0.0933, R superscript 2 equals 0.9817. Text boxes read Overcorrected and Undercorrected. A statistics box reads, mean: negative 3.57 plus or minus 2.02 D, range: plus 1.94 to negative 8.75 D. The image E showing a bar chart of percent of eyes versus accuracy of spherical equivalent to intended target in diopters. Horizontal axis label, Accuracy of SEQ to Intended Target D, with categories less than negative 1.50, negative 1.50 to negative 1.01, negative 1.00 to negative 0.51, negative 0.50 to negative 0.14, negative 0.13 to plus 0.13, plus 0.14 to plus 0.50, plus 0.51 to plus 1.00, plus 1.01 to plus 1.50, greater than plus 1.50. Vertical axis label, percent of Eyes, percent, from 0 percent to 50 percent. Bar values: less than negative 1.50 is 0 percent, negative 1.50 to negative 1.01 is 0 percent, negative 1.00 to negative 0.51 is 4.5 percent, negative 0.50 to negative 0.14 is 29 percent, negative 0.13 to plus 0.13 is 49 percent, plus 0.14 to plus 0.50 is 17 percent, plus 0.51 to plus 1.00 is 0.5 percent, plus 1.01 to plus 1.50 is 0 percent, greater than plus 1.50 is 0 percent. The image F showing a line plot of mean plus or minus standard deviation spherical equivalent versus time after surgery. Horizontal axis label, Time After Surgery months, with points Pre, 3 with 442 in parentheses and 12 with 442 in parentheses. Vertical axis label, Mean plus or minus SD SEQ D, from negative 5 to plus 1. Plotted mean values labeled at points: Pre negative 4.19, 3 months negative 0.51, 12 months negative 0.54. The image G showing a grouped bar chart of percent of eyes versus refractive astigmatism in diopters, with series labeled Postop and Preop. Horizontal axis label, Refractive Astigmatism D, with categories less than or equal to 0.25, 0.26 to 0.50, 0.51 to 0.75, 0.76 to 1.00, 1.01 to 1.25, 1.26 to 1.50, 1.51 to 2.00, 2.01 to 3.00 and greater than 3.00. Vertical axis label, percent of Eyes, percent, from 0 percent to 100 percent. Visible labeled bar values include Postop 86 percent and Preop 24 percent at less than or equal to 0.25, postop 11 percent and preop 23 percent at 0.26 to 0.50, postop 3 percent and preop19 percent at 0.51 to 0.75, postop 0 percent and preop 13 percent at 0.76 to 1.00, postop 0 percent and preop 7 percent at 1.01 to 1.25, postop 0 percent and preop 5 percent at 1.26 to 1.50, postop 0 percent and preop 5 percent at 1.51 to 2.00, postop 0 percent and preop 5 percent at 2.01 to 3.00, and postop 0 percent, preop 0 percent at greater than 3.00. The image H showing a scatter plot of surgically induced astigmatism vector versus target induced astigmatism vector. Horizontal axis label, Target induced astigmatism vector Diopters, from 0.0 to 3.0. Vertical axis label, Surgically induced astigmatism vector Diopters, from 0.0 to 3.0. Text boxes read Overcorrected and Undercorrected. Regression text reads, y equals 0.7782x plus 0.0506, R superscript 2 equals 0.8481. Additional text reads, TIA: 0.97 plus or minus 0.62 D, SIA: 0.79 plus or minus 0.53 D. The image I showing a horizontal bar chart of percent of eyes versus angle of error in degrees, with direction labels CC/Wise and C/Wise. Horizontal axis shows percent from 0 percent to 90 percent. Vertical axis label, Angle of Error degrees, with bins greater than 75, 65 to 75, 55 to 65, 45 to 55, 35 to 45, 25 to 35, 15 to 25, 5 to 15, negative 5 to 5, negative 15 to negative 5, negative 25 to negative 15, negative 35 to negative 25, negative 45 to negative 35, negative 55 to negative 45, negative 65 to negative 55, negative 75 to negative 65 and less than negative 75. The longest bar is at negative 5 to 5 with 84 percent. Other labeled bins include 5 to 15 at 4 percent, negative 15 to negative 5 at 4 percent, negative 25 to negative 15 at 2 percent, 15 to 25 at 1 percent, 25 to 35 at 1 percent, negative 35 to negative 25 at 0%, 35 to 45 at 1 percent, negative 45 to negative 35 at 1 percent, 45 to 55 at 0 percent, negative 55 to negative 45 at 0 percent, 55 to 65 at 1 percent, negative 65 to negative 55 at 0 percent, 65 to 75 at 0 percent, negative 75 to negative 65 at 0 percent, greater than 75 at 1 percent, and less than negative 75 at 1 percent.Nine standard graphs for myopia outcomes: histograms, scatter plots and a line plot. Figure 3Standard graphs reporting refractive outcomes in hyperopia group at 12 Months. (A) Cumulative histogram of postoperative uncorrected distance visual acuity (UDVA) and preoperative corrected distance visual acuity (CDVA) in distance eyes. (B) Comparison of postoperative UDVA and preoperative CDVA in distance eyes. (C) Histogram showing change in CDVA for all hyperopia eyes. (D) Scatter plot showing attempted vs achieved spherical equivalent (SEQ) for all hyperopia eyes. (The blue line indicates attempted SEQ= achieved SEQ, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line.) (E) Histogram showing accuracy to intended SEQ for all hyperopia eyes. (F) Stability of SEQ in all hyperopia eyes. The line plot (red line) shows the trend of mean SEQ over time. (G) Histogram showing preoperative and postoperative refractive astigmatism in all hyperopia eyes. (H) Scatter plot showing target induced astigmatism (TIA) vs surgically induced astigmatism (SIA) for the hyperopic astigmatic eyes. (The blue line indicates TIA = SIA, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line). (I) Histogram showing angle of error of refractive astigmatism for the hyperopic astigmatic eyes.The image A showing a grouped cumulative bar chart. X axis label, Cumulative Snellen VA (20/x or better), with categories 20/12.5, 20/16, 20/20, 20/25, 20/32, 20/40. Y axis label, Cumulative percent of Eyes, range 0 percent to 100 percent. Bars: postoperative uncorrected distance visual acuity and preoperative corrected distance visual acuity. Values shown: at 20/12.5, 4 percent and 0 percent; at 20/16, 35 percent and 4 percent; at 20/20, 90 percent and 100 percent; at 20/25, 96 percent and 100 percent; at 20/32, 99 percent and 100 percent; at 20/40, 99 percent and 100 percent. The image B showing a histogram. X axis label, Difference between uncorrected distance visual acuity and corrected distance visual acuity (Snellen Lines), categories 3 or More Worse, 2 Worse, 1 Worse, Same, 1 or More Better. Y axis label, percent of Eyes, range 0 percent to 90 percent. Bar values: 1 percent, 2 percent, 9 percent, 81 percent, 7 percent. The image C showing a histogram. X axis label, Change in Snellen Lines of corrected distance visual acuity, categories Loss 2 or More, Loss 1, No Change, Gain 1, Gain 2 or More. Y axis label, percent of Eyes, range 0 percent to 100 percent. Bar values: 0.5 percent, 2 percent, 89 percent, 7 percent, 1 percent. The image D showing a scatter plot with reference lines and a regression line. X axis label, Attempted SEQ (D), range minus 1.0 to plus 6.0. Y axis label, Achieved SEQ (D), range minus 1.0 to plus 6. Text: y equals 0.957x plus 0.0135; R superscript 2 equals 0.9754. Labels, Overcorrected and Undercorrected. Text box: mean: plus 2.37 plus or minus 1.25 D; range: plus 5.55 to minus 0.75 D. The image E showing a histogram. X axis label, Accuracy of SEQ to Intended Target (D), with bins labeled less than minus 1.5, minus 1.5 to minus 1.01, minus 1.0 to minus 0.51, minus 0.50 to minus 0.14, minus 0.13 to plus 0.13, plus 0.14 to plus 0.50, plus 0.51 to plus 1.0, plus 1.01 to plus 1.5, greater than plus 1.5. Y axis label, percent of Eyes, range 0 percent to 60 percent. Bar values shown: 0 percent, 0 percent, 8 percent, 26 percent, 53 percent, 11 percent, 2 percent, 0 percent, 0 percent. The image F showing a line plot. X axis label, Time After Surgery (months), with points Pre, 3 (196), 12 (196). Y axis label, Mean plus or minus SD SEQ (D), range minus 3 to plus 2. Labeled values at points: Pre at plus 1.59, 3 months at minus 0.77, 12 months at minus 0.69. The image G showing a grouped histogram. X axis label, Refractive Astigmatism (D), bins less than or equal to 0.25, 0.26 to 0.50, 0.51 to 0.75, 0.76 to 1.00, 1.01 to 1.25, 1.26 to 1.50, 1.51 to 2.00, 2.01 to 3.00, and greater than 3.00. Y axis label, percent of Eyes, range 0 percent to 90 percent. Postoperative values: 78 percent, 17 percent, 4 percent, 1 percent, 0 percent, 0 percent, 0 percent, 0 percent, 0 percent. Preoperative values: 43 percent, 36 percent, 10 percent, 4 percent, 4 percent, 1 percent, 1 percent, 1 percent, 1 percent. The image H showing a scatter plot with reference lines and a regression line. X axis label, Target induced astigmatism vector (D), range 0.0 to 3.0. Y axis label, Surgically induced astigmatism vector (D), range 0.0 to 3.0. Text: y equals 0.8972x plus 0.0502; R superscript 2 equals 0.8475. Labels, Overcorrected and Undercorrected. Text box: TIA 0.6 plus or minus 0.45 D; SIA 0.7 plus or minus 0.45 D. The image I showing a horizontal histogram. X axis label, Percentage Eyes (percent), range 0 percent to 90 percent. Y axis label, Angle of Error (degrees), with labeled bins greater than 75, 65 to 75, 55 to 65, 45 to 55, 35 to 45, 25 to 35, 15 to 25, 5 to 15, minus 5 to 5, minus 15 to minus 5, minus 25 to minus 15, minus 35 to minus 25, minus 45 to minus 35, minus 55 to minus 45, minus 65 to minus 55, minus 75 to minus 65, less than minus 75. Side labels: CCWise and C Wise. Percent values shown by bin: greater than 75 is 0.6 percent; 65 to 75 is 1 percent; 55 to 65 is 1 percent; 45 to 55 is 0.6 percent; 35 to 45 is 0 percent; 25 to 35 is 1 percent; 15 to 25 is 0.6 percent; 5 to 15 is 7 percent; minus 5 to 5 is 80 percent; minus 15 to minus 5 is 4 percent; minus 25 to minus 15 is 1 percent; minus 35 to minus 25 is 1 percent; minus 45 to minus 35 is 0.6 percent; minus 55 to minus 45 is 0 percent; minus 65 to minus 55 is 0 percent; minus 75 to minus 65 is 0.6 percent; less than minus 75 is 1 percent.9 standard graphs on hyperopia outcomes: histograms, scatter plots and a line plot.Table 2Visual Outcomes Preoperatively and at 12 months PostoperativelyParameterMyopia GroupHyperopia GroupDistance Eyes (n=221 Eyes)Near Eyes (n=221 Eyes)Binocular (n=221 Patients)Distance Eyes (n=98 Eyes)Near Eyes (n=98 Eyes)Binocular (n=98 Patients)Preop CDVA (logMAR), mean ± SD (range)−0.03 ± 0.03 (−0.10 to 0.15)−0.02 ± 0.04 (−0.04 to 0.15)−0.07 ± 0.05 (−0.20 to 0.09)−0.04 ± 0.03 (−0.04 to 0.10)−0.02 ± 0.09 (−0.10 to 0.30)−0.06 ± 0.05 (−0.20 to 0.20)Postop CDVA (logMAR), mean ± SD (range)−0.07 ± 0.05 (−0.30 to 0.15)−0.04 ± 0.06 (−0.10 to 0.20)−0.06 ± 0.05 (−0.30 to 0.20)−0.06 ± 0.06 (−0.30 to 0.05)−0.02 ± 0.07 (−0.20 to 0.30)−0.04 ± 0.07 (−0.30 to 0.30)Postop UDVA (logMAR), mean ± SD (range)−0.03 ± 0.13 (−0.20 to 0.20)0.35 ± 0.24 (−0.20 to 0.90)−0.07 ± 0.05 (−0.30 to 0.30)−0.03 ± 0.09 (−0.20 to 0.40)0.42 ± 0.24 (−0.09 to 0.90)−0.03 ± 0.07 (−0.20 to 0.20)Postop UNVA (logMAR), mean ± SD (range)0.10 ± 0.16 (0.00 to 0.70)0.01 ± 0.03 (0.00 to 0.30)0.00 ± 0.01 (0.00 to 0.10)0.22 ± 0.14 (0.00 to 0.50)0.01 ± 0.04 (0.00 to 0.30)0.00 ± 0.04 (0.00 to 0.30)Abbreviations: Preop, Preoperative; CDVA, Corrected distance visual acuity; SD, Standard deviation; Postop, Postoperative; UDVA, Uncorrected distance visual acuity; UNVA, Uncorrected near visual acuity. Standard graphs reporting refractive outcomes in myopia group at 12 Months. (A) Cumulative histogram of postoperative uncorrected distance visual acuity (UDVA) and preoperative corrected distance visual acuity (CDVA) in distance eyes. (B) Comparison of postoperative UDVA and preoperative CDVA in distance eyes. (C) Histogram showing change in CDVA for all myopia eyes. (D) Scatter plot showing attempted vs achieved spherical equivalent (SEQ) for all myopia eyes. (The blue line indicates attempted SEQ= achieved SEQ, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line.) (E) Histogram showing accuracy to intended SEQ for all myopia eyes. (F) Stability of SEQ in all myopia eyes. The line plot (red line) shows the trend of mean SEQ over time. (G) Histogram showing preoperative and postoperative refractive astigmatism in all myopia eyes. (H) Scatter plot showing target induced astigmatism (TIA) vs surgically induced astigmatism (SIA) for the myopic astigmatic eyes. (The blue line indicates TIA = SIA, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line). (I) Histogram showing angle of error of refractive astigmatism for the myopic astigmatic eyes. Standard graphs reporting refractive outcomes in hyperopia group at 12 Months. (A) Cumulative histogram of postoperative uncorrected distance visual acuity (UDVA) and preoperative corrected distance visual acuity (CDVA) in distance eyes. (B) Comparison of postoperative UDVA and preoperative CDVA in distance eyes. (C) Histogram showing change in CDVA for all hyperopia eyes. (D) Scatter plot showing attempted vs achieved spherical equivalent (SEQ) for all hyperopia eyes. (The blue line indicates attempted SEQ= achieved SEQ, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line.) (E) Histogram showing accuracy to intended SEQ for all hyperopia eyes. (F) Stability of SEQ in all hyperopia eyes. The line plot (red line) shows the trend of mean SEQ over time. (G) Histogram showing preoperative and postoperative refractive astigmatism in all hyperopia eyes. (H) Scatter plot showing target induced astigmatism (TIA) vs surgically induced astigmatism (SIA) for the hyperopic astigmatic eyes. (The blue line indicates TIA = SIA, green lines indicate ±0.50 D, and pink lines indicate ±1.00 D; the black line is the linear regression trend line). (I) Histogram showing angle of error of refractive astigmatism for the hyperopic astigmatic eyes. Table 2Visual Outcomes Preoperatively and at 12 months PostoperativelyParameterMyopia GroupHyperopia GroupDistance Eyes (n=221 Eyes)Near Eyes (n=221 Eyes)Binocular (n=221 Patients)Distance Eyes (n=98 Eyes)Near Eyes (n=98 Eyes)Binocular (n=98 Patients)Preop CDVA (logMAR), mean ± SD (range)−0.03 ± 0.03 (−0.10 to 0.15)−0.02 ± 0.04 (−0.04 to 0.15)−0.07 ± 0.05 (−0.20 to 0.09)−0.04 ± 0.03 (−0.04 to 0.10)−0.02 ± 0.09 (−0.10 to 0.30)−0.06 ± 0.05 (−0.20 to 0.20)Postop CDVA (logMAR), mean ± SD (range)−0.07 ± 0.05 (−0.30 to 0.15)−0.04 ± 0.06 (−0.10 to 0.20)−0.06 ± 0.05 (−0.30 to 0.20)−0.06 ± 0.06 (−0.30 to 0.05)−0.02 ± 0.07 (−0.20 to 0.30)−0.04 ± 0.07 (−0.30 to 0.30)Postop UDVA (logMAR), mean ± SD (range)−0.03 ± 0.13 (−0.20 to 0.20)0.35 ± 0.24 (−0.20 to 0.90)−0.07 ± 0.05 (−0.30 to 0.30)−0.03 ± 0.09 (−0.20 to 0.40)0.42 ± 0.24 (−0.09 to 0.90)−0.03 ± 0.07 (−0.20 to 0.20)Postop UNVA (logMAR), mean ± SD (range)0.10 ± 0.16 (0.00 to 0.70)0.01 ± 0.03 (0.00 to 0.30)0.00 ± 0.01 (0.00 to 0.10)0.22 ± 0.14 (0.00 to 0.50)0.01 ± 0.04 (0.00 to 0.30)0.00 ± 0.04 (0.00 to 0.30)Abbreviations: Preop, Preoperative; CDVA, Corrected distance visual acuity; SD, Standard deviation; Postop, Postoperative; UDVA, Uncorrected distance visual acuity; UNVA, Uncorrected near visual acuity. Visual Outcomes Preoperatively and at 12 months Postoperatively Abbreviations: Preop, Preoperative; CDVA, Corrected distance visual acuity; SD, Standard deviation; Postop, Postoperative; UDVA, Uncorrected distance visual acuity; UNVA, Uncorrected near visual acuity. In myopic patients, UDVA at 12 months was 20/20 or better in 90% of distance eyes, while 93% achieved UDVA equal to or better than preoperative CDVA and 96% had UDVA within 1 line of preoperative CDVA (Figure 2A and B). Binocularly, UDVA was 20/20 or better in 98% of patients, and UNVA was N6 (20/40) or better in 99% of patients; mean binocular UDVA and UNVA were −0.07±0.05 logMAR and 0.00±0.01 logMAR, respectively. In hyperopic patients, 12-month UDVA was 20/20 or better in 90% of distance eyes, with 88% achieving UDVA that was the same or better than preoperative CDVA and 97% having UDVA within 1 line of preoperative CDVA (Figure 3A and B). Binocular UDVA was 20/20 or better in 93% of patients, while binocular UNVA of N6 (20/40) or better was achieved in 96% of patients; mean binocular UDVA and UNVA were −0.03±0.07 logMAR and 0.00±0.04 logMAR, respectively. Refractive Outcomes Table 3 shows the SEQ data of the distance and near eyes in both groups. In myopic patients, mean attempted SEQ in the distance eyes was −4.11±1.92 D and mean achieved SEQ was −4.05±1.90 D. In the near eyes, mean attempted and achieved SEQ was −3.06±1.96 D and −3.25±2.02 D, respectively. The coefficient of determination (R2) between attempted and achieved SEQ was 0.9817 (Figure 2D) and SEQ was within ±0.50 D of target in 95% of eyes and within ±1.00 D in 100% of eyes (Figure 2E). Manifest SEQ was stable between the 3-month and 12-month postoperative visits with no eyes showing SEQ change >0.50 D (Figure 2F). Residual astigmatism was ≤0.50 D and ≤1.00 D in 97% and 100% of eyes, respectively (Figure 2G). In astigmatic eyes (n=396), the scatter plot for target induced astigmatism (TIA) vs surgically induced astigmatism (SIA) showed R2 value of 0.8481 and slight under-correction of astigmatism (Figure 2H). Angle of error (AoE) analysis showed that 84% of astigmatic eyes were within ±5° of the intended meridian; arithmetic mean AoE was 0.5°±1.3° and absolute mean was 4.2°±12.9° (Figure 2I).Table 3Refractive Analysis Preoperatively and at 12 months PostoperativelyParameterMyopia GroupHyperopia GroupDistance Eyes (n=221)Near Eyes (n=221)Distance Eyes (n=98)Near Eyes (n=98)Preop SEQ (D), mean ± SD (range)−4.11 ± 1.92 (−0.62 to −8.75)−4.29 ± 1.96 (−0.75 to −9.00)+1.54 ± 0.87 (−0.75 to +3.25)+1.65 ± 1.00 (−0.63 to +4.25)Target (D), mean ± SD (range)0.00 ± 0.00 (0.00 to 0.00)−1.23 ± 0.34 (−0.40 to −2.00)0.00 ± 0.00 (0.00 to 0.00)−1.56 ± 0.23 (−2.00 to −0.90)Attempted SEQ (D), mean ± SD (range)−4.11 ± 1.92 (−0.62 to −8.75)−3.06 ± 1.96 (−0.75 to −7.75)+1.54 ± 0.87 (−0.75 to +3.25)+3.20 ± 0.97 (+0.88 to +5.55)Achieved SEQ (D), mean ± SD (range)−4.05 ± 1.90 (+0.13 to −9.25)−3.25 ± 2.02 (+0.75 to −8.25)+1.56 ± 0.87 (−0.75 to +3.38)+3.02 ± 0.93 (−0.63 to +5.00)Postop SEQ (D), mean ± SD (range)−0.04 ± 0.20 (+0.63 to −0.75)−1.05 ± 0.42 (−0.25 to −2.25)−0.02 ± 0.21 (−0.75 to +0.75)−1.41 ± 0.40 (−2.25 to −0.50)Accuracy relative to the target (D), mean ± SD (range)−0.04 ± 0.19 (+0.63 to −0.75)+0.18 ± 0.28 (+0.50 to −0.78)−0.02 ± 0.20 (−0.75 to +0.75)+0.15 ± 0.33 (−0.90 to +0.65)Abbreviations: Preop, Preoperative; SEQ, Spherical equivalent; D, Diopter; SD, Standard deviation; Postop, Postoperative. Table 3Refractive Analysis Preoperatively and at 12 months PostoperativelyParameterMyopia GroupHyperopia GroupDistance Eyes (n=221)Near Eyes (n=221)Distance Eyes (n=98)Near Eyes (n=98)Preop SEQ (D), mean ± SD (range)−4.11 ± 1.92 (−0.62 to −8.75)−4.29 ± 1.96 (−0.75 to −9.00)+1.54 ± 0.87 (−0.75 to +3.25)+1.65 ± 1.00 (−0.63 to +4.25)Target (D), mean ± SD (range)0.00 ± 0.00 (0.00 to 0.00)−1.23 ± 0.34 (−0.40 to −2.00)0.00 ± 0.00 (0.00 to 0.00)−1.56 ± 0.23 (−2.00 to −0.90)Attempted SEQ (D), mean ± SD (range)−4.11 ± 1.92 (−0.62 to −8.75)−3.06 ± 1.96 (−0.75 to −7.75)+1.54 ± 0.87 (−0.75 to +3.25)+3.20 ± 0.97 (+0.88 to +5.55)Achieved SEQ (D), mean ± SD (range)−4.05 ± 1.90 (+0.13 to −9.25)−3.25 ± 2.02 (+0.75 to −8.25)+1.56 ± 0.87 (−0.75 to +3.38)+3.02 ± 0.93 (−0.63 to +5.00)Postop SEQ (D), mean ± SD (range)−0.04 ± 0.20 (+0.63 to −0.75)−1.05 ± 0.42 (−0.25 to −2.25)−0.02 ± 0.21 (−0.75 to +0.75)−1.41 ± 0.40 (−2.25 to −0.50)Accuracy relative to the target (D), mean ± SD (range)−0.04 ± 0.19 (+0.63 to −0.75)+0.18 ± 0.28 (+0.50 to −0.78)−0.02 ± 0.20 (−0.75 to +0.75)+0.15 ± 0.33 (−0.90 to +0.65)Abbreviations: Preop, Preoperative; SEQ, Spherical equivalent; D, Diopter; SD, Standard deviation; Postop, Postoperative. Refractive Analysis Preoperatively and at 12 months Postoperatively Abbreviations: Preop, Preoperative; SEQ, Spherical equivalent; D, Diopter; SD, Standard deviation; Postop, Postoperative. In hyperopic patients, mean attempted SEQ in the distance eyes was +1.54±0.87 D and mean achieved was +1.56±0.87 D. In the near eyes, mean attempted and achieved SEQ were +3.20±0.97 D and +3.02±0.93 D, respectively. R2 between attempted and achieved SEQ was 0.9754 (Figure 3D) and SEQ was within ±0.50 D of intended target in 90% of eyes, while 100% of eyes were within ±1.00 D (Figure 3E). SEQ remained stable from the 3-month follow-up onwards and no eyes showed change >0.50 D (Figure 3F). Residual astigmatism was ≤0.50 D and ≤1.00 D in 95% and 100% of eyes, respectively (Figure 3G). In astigmatic eyes (n=154), R2 between TIA and SIA was 0.8475 (Figure 3H). Arithmetic mean AoE was 0.8°±18.3° and absolute mean was 6.5°±17.1°; 80% of eyes were within ±5° of the intended meridian (Figure 3I). Safety In the myopia group, 87% of eyes maintained preoperative CDVA, while 12% of eyes gained one or more Snellen lines of CDVA and 1% of eyes lost one line of CDVA (Figure 2C). No eyes lost two or more lines of CDVA. In the hyperopia group, 89% of eyes had no change in CDVA, while 8% of eyes gained one or more lines (Figure 3C). Loss of two or more lines of CDVA was seen in one eye (0.5%). In both groups, no eyes required enhancement or re-treatment at the 12-month visit, although future enhancement might be considered in roughly 5% of patients for residual refractive error. There were no intraoperative or postoperative complications in either group other than transient dry eye symptoms. Patient-Reported Outcomes A total of 237 treated patients voluntarily completed the satisfaction questionnaire (Table 4); 137 patients (43.0% of the final cohort) were assessed at 3–6 months, and 100 patients (31.4% of the final cohort) were assessed at 12 months postoperatively (Figure 1). Respondent subsets at both timepoints were not comprised of the same patients.Table 4Patient QuestionnaireQuestionAnswer(s)3-6 Months (%) n = 13712 Months (%) n = 100What was your main source of information about PRESBYOND?My doctor17.8%13.9%Print media0.00%0.00%Digital media (including websites, forums, social networks)36.8%36.5%Relatives/friends45.4%48.7%Other0.0%0.9%What was the main reason for choosing PRESBYOND?Allows for sharp vision at all distances32.8%38.0%Provides immediate effect16.9%17.8%Less invasive than other surgical procedures3.8%7.0%Well tolerated by most patients4.9%3.9%Recommended to me by my doctor as most appropriate solution41.5%33.3%How would you describe your experience on the day of the procedure?I felt safe and relaxed the entire time27.1%27.1%It was easier than I thought41.6%42.6%I was nervous before the procedure and tense during it28.3%26.4%It was harder than I expected3.0%3.9%How do you rate the improvement in your vision after the procedure?The improvement occurred very quickly, within a few hours23.8%35.2%Improvement occurred after a few days38.1%34.3%I still get blurry vision sometimes32.0%27.6%Hard to say6.1%2.9%How do you rate the quality of your vision after the procedure?Excellent15.3%27.0%Good57.7%47.0%Just right (“satisfactory”)24.8%18.0%Weak2.2%8.0%Very weak0.0%0.0%Knowing everything you know now, are you happy with the decision you made?Yes64.2%66.0%Yes, but it’s a pity I didn’t decide to have the procedure earlier28.5%23.0%I do not know6.6%9.0%No0.7%2.0%Would you recommend PRESBYOND treatment to your friends and family?Yes90.5%87.0%No0.0%2.0%I do not know9.5%11.0% Table 4Patient QuestionnaireQuestionAnswer(s)3-6 Months (%) n = 13712 Months (%) n = 100What was your main source of information about PRESBYOND?My doctor17.8%13.9%Print media0.00%0.00%Digital media (including websites, forums, social networks)36.8%36.5%Relatives/friends45.4%48.7%Other0.0%0.9%What was the main reason for choosing PRESBYOND?Allows for sharp vision at all distances32.8%38.0%Provides immediate effect16.9%17.8%Less invasive than other surgical procedures3.8%7.0%Well tolerated by most patients4.9%3.9%Recommended to me by my doctor as most appropriate solution41.5%33.3%How would you describe your experience on the day of the procedure?I felt safe and relaxed the entire time27.1%27.1%It was easier than I thought41.6%42.6%I was nervous before the procedure and tense during it28.3%26.4%It was harder than I expected3.0%3.9%How do you rate the improvement in your vision after the procedure?The improvement occurred very quickly, within a few hours23.8%35.2%Improvement occurred after a few days38.1%34.3%I still get blurry vision sometimes32.0%27.6%Hard to say6.1%2.9%How do you rate the quality of your vision after the procedure?Excellent15.3%27.0%Good57.7%47.0%Just right (“satisfactory”)24.8%18.0%Weak2.2%8.0%Very weak0.0%0.0%Knowing everything you know now, are you happy with the decision you made?Yes64.2%66.0%Yes, but it’s a pity I didn’t decide to have the procedure earlier28.5%23.0%I do not know6.6%9.0%No0.7%2.0%Would you recommend PRESBYOND treatment to your friends and family?Yes90.5%87.0%No0.0%2.0%I do not know9.5%11.0% Patient Questionnaire The main source of information about the procedure was word of mouth, as 45–49% of patients learned about the procedure from relatives and friends. Other commonly reported sources were websites (36–37%) and treating clinicians (14–18%). The main reasons for choosing the procedure were a recommendation by their doctor as the best and most appropriate solution (33–42%) and patients’ expectation that the procedure provides sharp vision at all distances (33–38%). The surgical experience was described as safe or easier than expected by 69–70% of patients. Most patients (62–70%) noticed an improvement in distance and near vision within a few hours to a few days; at 12 months, 97% of patients reported improvement in vision. One year after treatment, 92% of patients rated their quality of vision from satisfactory (“Just right”) to excellent, 89% of patients were happy with their decision to undergo the procedure, and 87% of patients would recommend it to others. Discussion This study evaluated clinical and patient-reported outcomes following non-linear aspheric micro-monovision LASIK (PRESBYOND) for myopic and hyperopic presbyopic patients. Over 12 months of follow-up, the procedure was shown to be safe and well-tolerated with favorable visual and refractive outcomes and high patient satisfaction. Binocular UDVA of 20/20 or better was achieved in 98% of myopic patients and 93% of hyperopic patients, while binocular UNVA was N6 (20/40) or better in 99% and 96% of patients, respectively. The high effectiveness observed in this study is consistent with the existing literature on non-linear aspheric micro-monovision LASIK. In a cohort of presbyopic patients with hyperopic astigmatism, Reinstein et al reported binocular UDVA of 20/20 in 95% of patients and observed that 100% of patients could read J5 (20/40) or better.24 In patients with presbyopia and myopia, Hernández-Lucena et al observed binocular UDVA of 20/20 in 96.5% of patients and binocular UNVA of 20/32 or better in 97.2% of patients,26 while Zhang et al found 95% of patients to achieve UDVA of 20/20 or better and UNVA of J2 (20/25) or better simultaneously.18 The procedure showed high accuracy in our study: in the myopia and hyperopia groups, 95% and 90% of eyes were within ±0.50 D, respectively, and 100% of eyes were within ±1.00 D of intended SEQ in both groups. Similarly high accuracy has been reported in previous studies. In a study by Russo et al, SEQ within ±0.50 D and ±1.00 D of target was achieved in 81% and 100% of eyes with myopic presbyopia, respectively, and 83% and 99% of eyes with hyperopic presbyopia, respectively.11 Reinstein et al observed achieved SEQ to be within ±0.50 D in 92% and within ±1.00 D in 99% of eyes with myopic astigmatism and presbyopia,23 while Zhang et al found 93% of eyes to be within ±0.50 D of target SEQ in a cohort with presbyopia and myopia.18 Most of the respondents assessed at 3–6 months and 12 months reported experiencing improvement in their distance and near vision within hours to days after treatment. Additionally, the vast majority of patients in both myopia and hyperopia groups achieved binocular UDVA and UNVA equal to or better than 20/20 and N6, respectively, as described previously. These results suggest that the procedure fulfilled respondents’ expectations as implied from their stated reasons for choosing the procedure, namely, sharp vision at all distances (33–38% of patients) and immediate effect (17–18%). Mean postoperative UDVA and UNVA were better binocularly than monocularly; this may be attributable to binocular neural summation due to the extended depth of focus created by the non-linear aspheric micro-monovision protocol, as observed in previous studies.11,26 The proportion of patients that did not experience a clear improvement in vision decreased from 6% at 3–6 months to 3% at 12 months, suggesting adaptation to anisometropia over time. Previous studies have shown that neuroadaptation may continue up to 6–12 months following this procedure.11,27 The majority of respondents (92–98%) rated their postoperative quality of vision from satisfactory to excellent. The proportion of patients reporting excellent visual quality increased from 3–6 months to 12 months postoperatively (15% vs 27%, respectively). Notably, no retreatments were performed in this study, and improvements in vision occurred without the need for enhancements. Previous studies have demonstrated good optical quality with preserved contrast sensitivity and stereoacuity following this procedure.28 There are a few studies that have reported postoperative visual symptoms: in a study by Fu et al,21 night vision disturbances were the most common symptoms reported by patients, while Brar et al13 reported mild dysphotopsia in 6.6% of patients. However, night vision disturbances and dysphotopsia due to halos and glare are possible adverse events that can be associated with any LASIK procedure.29,30 In the current study, 89% of patients assessed at 1 year postoperatively were happy with their decision to undergo the procedure and 87% would recommend it to others. Notably, these satisfaction levels were achieved without any enhancements. Approximately 5% of patients had residual refractive errors but declined retreatment; these patients may be considered for enhancement in the future depending on their satisfaction with their vision over time. It is possible that even higher satisfaction could have been observed in the current study had retreatment been performed. Similarly, high patient satisfaction has been reported in previous studies. Fu et al21 reported that all patients rated their satisfaction with the procedure from passable to extremely satisfied, while Brar et al13 reported mean satisfaction scores of 97.97±2.13, 99.36±0.64 and 96.84±2.36 for distance, intermediate, and near, respectively. Other studies have reported high satisfaction rates of 94–97%.12,14,19 In the current study, non-linear aspheric micro-monovision LASIK was well-tolerated, with 69–70% of respondents describing a relaxed or easier than expected surgical experience. In addition, the procedure showed high safety with no operative or postoperative complications other than transient dry eye, which is a common side effect after LASIK.31 The rate of loss of two or more lines of CDVA was 0.0% in the myopia group and 0.5% in the hyperopia group, which is consistent with previous studies on this procedure reporting rates of 0.0–0.3%.14,23,24 The presented refractive and satisfaction results concern patients without any enhancements over 12 months of follow-up. This is consistent with studies by Brar et al13 and Hernández-Lucena et al26 where no enhancement was required in any eye in the study population over 6 months of follow-up. Other studies have reported varying rates of retreatment: Russo et al11 reported 6-month retreatment rates of 5% and 8% in myopic and hyperopic eyes with presbyopia, respectively; Reinstein et al24 observed a 22% retreatment rate in patients with presbyopia and hyperopia over a median follow-up of 12.5 months; Falcon et al14 found that 13.9% of patients required enhancement over a follow-up range of 1 to 28 months after surgery. Variations between studies may be due to differences in patient demographics as well as surgeon preferences with regard to acceptable levels of residual refractive error. As noted previously, patient satisfaction levels following non-linear aspheric micro-monovision LASIK are extremely high, and we recommend that satisfaction should be considered alongside residual refractive error when deciding on whether and when to consider an enhancement. It is acknowledged that inferences related to patient perspectives in the current study are drawn from a non-validated purpose-made questionnaire. The use of validated refractive surgery PRO instruments like the PROWL (Patient-Reported Outcomes With Laser In Situ Keratomileusis),32 NEI-RQL (National Eye Institute–Refractive Error Quality of Life),33 RSVP (Refractive Status and Vision Profile),34 and QIRC (Quality of Life Impact of Refractive Correction)35 would have imparted greater reliability and validity to our observations. However, our aim was to assess patients’ motivations for surgery and their intraoperative experience, in addition to satisfaction, which would not have been possible with the currently validated questionnaires, thereby necessitating the use of a purpose-made questionnaire. The current study has several limitations due to its retrospective real-world nature, which must also be acknowledged. The lack of randomization, sample size calculation, and adjustment for inter-eye correlation could have introduced statistical bias. Since only routinely collected clinical data were analyzed, a consistent dataset could not be obtained for domains like visual phenomena, depth perception, or ocular symptoms. The generalizability of the results is limited by the inclusion of patients from a single tertiary eye care center, operated on by a single surgeon experienced with PRESBYOND treatment. Loss to follow-up could have introduced non-response bias as patients dissatisfied with the procedure may be less likely to continue follow-up. Since the PRO questionnaire was administered at the clinic, respondents’ awareness of the investigators could have introduced a degree of response bias. The medium-term study duration precludes definitive conclusions about the durability of the results. Additionally, the assessment of immediate postoperative experiences at 12 months postoperatively could be susceptible to recall bias. However, it is worth mentioning that the responses of our patients were consistent across time. Long-term prospective randomized studies using validated PRO questionnaires are required to confirm the durability and reliability of our findings and further characterize PROs with this procedure. Future studies can additionally assess possible complications of LASIK and monovision, such as dry eyes, visual disturbances like glare and halos, diplopia, and difficulties in depth perception. It would also be interesting to investigate the correlation of visual and ocular symptoms with postoperative patient satisfaction. Finally, given that patients noted a fast visual recovery at all distances, it would be important to validate that response by providing a questionnaire in the first day or week postoperatively. Conclusion In conclusion, non-linear aspheric micro-monovision LASIK (PRESBYOND) performed in presbyopic patients with myopia and hyperopia demonstrated favorable visual and refractive outcomes, with high accuracy, medium-term stability of refractive correction, and a favorable safety profile. Patient-reported outcomes were assessed using a purpose-made non-validated questionnaire, and the procedure was found to have an uneventful surgical course, rapid postoperative visual rehabilitation, and high levels of satisfaction among the majority of respondents.